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DNA loopingNuclear receptors (NRs) are key transcriptional regulators of metazoan physiology and metabolism. Different
NRs bind to similar or even identical core response elements; however, they regulate transcription in a highly
receptor- and gene-speciﬁc manner. These differences in gene activation can most likely be accounted for by
mechanisms involving receptor-speciﬁc interactions with DNA as well as receptor-speciﬁc interactions with
protein complexes binding to adjacent and distant DNA sequences. Here, we review key molecular aspects of
transactivation by NRs with special emphasis on the recent advances in the molecular mechanisms
responsible for receptor- and gene-speciﬁc transcriptional activation. This article is part of a Special Issue
entitled: Translating nuclear receptors from health to disease.slating nuclear receptors from
45 6550 2467.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Nuclear receptors (NRs) are a family of ligand-activated transcrip-
tion factors (TFs) that regulate transcription of target genes through
binding to speciﬁc response elements (REs). NRs regulate several
aspects of human physiology and alterations in NR signaling have
been implicated in diseases such as type II diabetes mellitus, cancer,
and cardiovascular diseases [1,28,32,74,98,138]. The drugability of the
NR ligand binding domain combined with the involvement of these
receptors in life-threatening diseases have made them subjects of
intense pharmacological research. At the same time the ability to
easily control the activity of the receptors with lipophilic ligands has
made NRs attractive targets for basic research aiming at understand-
ing mechanisms of transcriptional regulation.
NRs can be subdivided into three classes according to the
organization of their REs and their dimerization properties [3,91].
Class I NRs bind as homodimers to REs organized as palindromic or
inverted palindromic hexanucleotide repeats separated by 3 bp. This
group of receptors includes the classical steroid receptors (i.e.,
estrogen receptors (ERs), androgen receptor (AR), progesterone
receptors (PRs), mineralocorticoid receptor (MR), and glucocorticoid
receptor (GR)) that are speciﬁcally activated by high afﬁnity
hormones. Unliganded steroid receptors (except ER) are generally
found in the cytoplasm in complex with heat shock proteins.
Hormone binding induces a conformational change, which results indissociation from the cytoplasmic heat shock protein complex and
transport into the nucleus, where the receptor can bind to its cognate
REs and activate transcription of target genes [6,33,39,60,84,116].
Class II receptors all bind REs consisting of two direct hexanucleotide
repeats spaced by 1–5 bp (DR1–5 elements) as obligate heterodimers
with retinoid X receptor (RXR). This group of receptors includes
endocrine receptors (e.g., thyroid hormone receptors (TRs) and
retinoic acid receptors (RARs)) that are activated by hormonal
ligands. These receptors are predominantly found in the nucleus
even in the absence of ligand [7,90,162], where they associate with
corepressors at REs resulting in repression of transcription
[20,24,59,61]. Upon ligand binding, a conformational change favors
displacement of corepressor complexes and recruitment of coactiva-
tor complexes resulting in transcriptional activation of target genes
[24,79,110]. Class II NRs also contains adopted orphan receptors such
as the peroxisome proliferator-activated receptors (PPARs) and liver
X receptors (LXRs). These receptors are found primarily in the nucleus
[7,15,90,117], where they are activated by a multitude of different
lipophilic metabolites ranging from abundant low-afﬁnity ligands to
less abundant high afﬁnity ligands. Thus, this class of receptors
functions as metabolic sensors regulating gene programs according to
the metabolic status of the cell. Class III NRs (e.g., estrogen receptor-
related receptors (ERRs), steroidogenic factor 1 (SF1), and Rev-Erb)
bind either as monomers to hexanucleotide sequences or as dimers to
composite elements (e.g., DRs). This group consists mostly of orphan
receptors for which no endogenous ligand has yet been identiﬁed and
these receptors have thus not received as much attention as the
endocrine and adopted orphan receptors [42].
NRs have a common structural organization consisting of four
distinct domains (Fig. 1). The N-terminal domain (NTD, A/B-domain)
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transactivation function, referred to as activation function 1 (AF1).
The central part of NRs is the highly conserved DNA binding domain
(DBD, C-domain). Following the DBD, a hinge region (D-domain)
confers spatial ﬂexibility to the receptors and links the DBD with the
second most conserved region of NRs: The ligand binding domain
(LBD, E-domain), which contains the ligand-dependent activation
function 2 (AF2). In the following we will ﬁrst review the impact of
each of these domains on gene and cell type-speciﬁc activation of
target genes and then discuss recent ﬁndings highlighting the
importance of NR crosstalk with other TFs.
2. TheDBD and C-terminal extension (CTE) and target site speciﬁcity
The core DBD (Fig. 2) consists of approximately 66 residues and is
by far the most conserved domain of NRs. The hallmark of the DBD is
two highly conserved zinc-ﬁnger motifs (Zn-I and Zn-II), in which a
zinc ion is tetrahedrally coordinated by four highly conserved cysteine
residues [3,35]. The DBD folds into two perpendicular α-helices that
constitute the core structure of the DBD. The ﬁrst α-helix (the
recognition helix) forms between the two zinc-ﬁnger motifs and
interacts directly with the major groove of RE half sites in a DNA
sequence-dependent manner [50]. The DNA sequence speciﬁcity of
NRs was ﬁrst established for ER and GR [72,109,131,132,144,150].
However, it was soon discovered that several different NRs selectively
bind the same DNA sequences [151], raising the question how different
NRs can regulate distinct sets of target genes through binding of highly
similar REs. The residues critical for sequence-speciﬁc DNA binding
within the ﬁrstα-helix are termed the P-box [149]. The secondα-helix
extends beyond Zn-II and is packed against the ﬁrst α-helix in aFig. 1. General structural and functional organization of NRs. Top: Schematic outline of the ge
to receptor function. Functions that map to the individual domains are summarized as bulle
DBD, hinge and LBD. The DBD and LBD are structurally highly conserved among NRs, wher
details. NLS; nuclear localization signal, NES; nuclear export signal, AF; activation function,perpendicular manner, which stabilizes the DBD structure and confers
non-speciﬁc backbone interactions with DNA; however, this second α-
helix does notmake base-speciﬁc contacts with RE half site nucleotides.
The secondzinc-ﬁnger (Zn-II) contains theD-box,which for someNRs is
involved in dimerization [160,161].
In addition to the core DBD the C-terminal extension (CTE)
constitutes an important determinant of sequence-speciﬁc DNA
binding formany NRs. The CTE is comprised of the ﬁrst 10–30 residues
following the fully conserved ‘GM’ (G, glycine; M, methionine)
sequence of the core DBD and is, unlike the core DBD, highly variable
between the different NRs (Fig. 2). Many NR CTEs have arginine-rich
motifs that expand theNR-DNA interaction surface beyond the core RE
by minor groove interactions with spacer and/or ﬂanking DNA
sequences [19,38,85,94]. Such interactions are highly dependent on
the width of the minor groove DNA, which is determined by the DNA
sequence [126]. This indicates that the DNA sequences ﬂanking REs
contribute to selective DNA binding of a subset of NRs.
Class I NRs bind as homodimers to REs consisting of two
hexanucleotide half sites, organized as palindromic or inverted
palindromic repeats, separated by an invariant 3 bp spacer. ERs
preferentially bind the hexanucleotide half site consensus sequence
5'-AGGTCA-3', whereas the consensus halfsite sequence of all other
class I receptors is 5'-AGAACA-3'. Moreover, AR has been shown to
bind REs organized as direct repeats [133], which confers AR-speciﬁc
regulation of target genes in vivo [46,47,130]. The ERs are also
functionally unique among the class I NRs, as they are able to function
not only as homodimers, but also as ERα/ERβ heterodimers [112]. It
has been shown that ER heterodimers are functionally distinct from
ER homodimers in their ability to bind REs and to activate
transcription of a subset of target genes in vivo [106]. Besides theneral structural organization of NRs. The NTD, DBD, hinge and LBD contribute differently
tpoints. Not all functions apply to all NRs. Bottom: Structure of the DNA-bound PPARγ
eas the NTD and hinge region lacks structural and sequence conservation. See text for
PTM; posttranslational modiﬁcation. [PDB ID; 3dzy].
Fig. 2. Organization of the DNA binding domain (DBD) of NRs. (A) Schematic representation of the DBD functional motifs involved in DNA binding and dimerization. The core DBD is
highly conserved, whereas conservation is not maintained in the CTE/hinge region. (B) Structural organization of NR core DBDs with location of functional motifs shown. (C)
Different classes of NRs preferentially bind DNA as homodimers in a head-to-head fashion (class I NRs), as heterodimers in a head-to-tail fashion (class II NRs) or as monomers (class
III NRs). [PDB ID: (B) 3dzy; (C) 1ynw, 1lo1, 1hcq].
826 M.M. Aagaard et al. / Biochimica et Biophysica Acta 1812 (2011) 824–835apparent AR-speciﬁc ability to bind REs organized as direct repeats, an
intriguing question is how the different homodimers selectively bind
highly similar REs. As mentioned above, the P-box sequence of the
recognition helix confers some NR selectivity towards speciﬁc REs. For
instance, changing a single residue in the P-box sequence of ERs to
that of the GR P-box changes the RE selectivity of ER towards GR REs
and vice versa [163]. However, this does not explain the differential
ability of, e.g., ERα and ERβ to bind REs in vivo [86], because the
residues that make base-speciﬁc interactions with RE halfsites are
fully conserved between the two subtypes.
The stronger DNA binding conferred by ERα has been suggested to
be a result of an ‘RGGR’ motif known as a ‘GRIP-Box’ located in the
CTE of ERα, but not ERβ [94]. This and similar arginine-rich motifs in
other NRs map to the same region of the CTE (Fig. 2) and interact
directly with the minor groove of DNA upstream from the RE halfsite
[38,85]. Such minor groove DNA interactions contribute to, and in
some cases are even required for, functional DNA binding by these
NRs. Similar regions of, e.g., AR have been shown in vitro to be highly
important for DNA binding [130], albeit structural data conﬁrming
direct interaction with DNA are lacking. Recently, Tanner et al.
identiﬁed a region of only ﬁve residues (RKLKK) in the CTE of AR
which is important for multiple functions, including nuclear localiza-
tion, DNA binding, receptor protein stability, and transactivation
potential [147]. Interestingly, this RKLKK motif maps to the same
region of the CTE as the RGGR and RFGR motifs that has been shown
for other NRs to interact with minor groove DNA ﬂanking the RE. This
suggests that RKLKK may constitute an alternative motif able to
interact with minor groove DNA, thereby contributing to AR-selective
binding of REs.
The P-box sequence is also fully conserved between AR, GR, MR,
and PRs, suggesting that selective binding of these NRs to REs is not
conferred by this region of their DBDs. Instead it is becoming
increasingly clear that the non-conserved CTE contributes to selective
binding of these NRs to REs. PR, MR and GR contain a highly similar
RKXKK motif at the same position in the CTE, which could possibly
contribute to multiple functions of these NRs in a similar manner as
shown for AR. For instance, it has been shown for PR that at least partof this motif directly interacts with minor groove DNA ﬂanking the RE
and that this interaction is important for PR binding to REs [125].
Similarly, the RKXKK motif found at the same position in GR has been
shown to be directly responsible for interaction with the cofactor Bcl-
2 associated Athanogene 1M (Bag-1M), a cofactor reported to reduce
GR binding to DNA, and to be involved in recruitment of corepressors
such as NCoR and SMRT thereby attenuating GR transactivation
potential [57,58]. Moreover, it has been demonstrated that acetylation
of a cluster of lysine residues directly ﬂanking this RKXKK motif
reduces the ability of GR to bind REs [101]. Taken together, current
data suggest that the non-conserved CTEs of class I NRs contribute to
selective RE binding directly (e.g., by interaction with minor groove),
and indirectly (e.g., by posttranslational modiﬁcations (PTMs) and
cofactor recruitment that in turn modulates the RE binding properties
of the NRs).
Class II NRs bind REs as obligate heterodimers with RXR, and these
heterodimers recognize REs organized as two direct repeats of the 5'-
AGGTCA-3' consensus half site sequence spaced by 1–5 bp (DR1–5
elements) [119], reviewed in ref. [118]. Generally, different hetero-
dimerizing receptors selectively bind REs with a speciﬁc spacing
between halfsites. This selectivity of NRs towards one particular type
of RE is due to the requirement of extensive protein–protein
interactions between the heterodimerizing partners for stable DNA
binding. Thus, adding or removing a single base pair in the spacer
(e.g., changing from a DR1 to a DR2 element) displaces the
heterodimerizing partners by a distance and rotation of approxi-
mately 3.4 Å and 35°, respectively, which is incompatible with the
protein–protein interactions required for heterodimerization. Conse-
quently, the spacing between half sites is a key determinant of high
afﬁnity binding of heterodimers to speciﬁc REs.
Most heterodimers bind REs with RXR occupying the 5'-halfsite
and the dimerization partner occupying the 3'-halfsite [160,161]. In
these cases, the CTE of the dimerization partner will be located at the
center of the dimeric complex, due to the head-to-tail conﬁguration of
the heterodimer and will contribute to selective binding to REs with
the correct spacing, while preventing binding to REs with incorrect
spacing, e.g., as shown for the RXR:TR heterodimer [119]. In contrast,
Fig. 3. NRs gain selective RE binding by exploiting multiple sequence and structural
features of DNA. Most NRs bind REs with a speciﬁc halfsite organization, consensus
sequence, and spacer length. Additional RE binding selectivity can be obtained through
recognition of structural features of minor groove DNA of ﬂanking and/or spacer
sequences. Finally, crosstalk with other TFs contributes to NR-speciﬁc binding in a RE-
dependent manner.
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which positions the CTE in the periphery of the heterodimer in close
proximity to the 5'-extension sequence. The recently solved crystal
structure of the PPARγ:RXRα heterodimer complexed to a consensus
PPAR RE, clearly shows that the CTE of PPARγ is deeply buried in the
DNA minor groove directly upstream of the core DR1 [19].
Interestingly, the region of the PPAR CTE buried in the minor groove
(‘RFGR’) closely resembles the GRIP-box sequence shown to be
important for selective RE binding by many NRs, including ERα
(described above), and class III NRs (see below).
While most heterodimers are restricted to binding REs with a
speciﬁc spacer length and polarity, the RXR:RARα heterodimer has
been shown to bind both DR1 and DR5 elements with RARα
occupying the 5'- and 3'-halfsite, respectively. Intriguingly, shifting
the polarity by binding DR1 rather than DR5 elements has been
reported to shift the activity of the RARα-RXR heterodimer from an
activator to a repressor of RAR target genes, due to differences in the
ability of the two types of RARα-RXR heterodimer to recruit
coactivators and corepressors [77].
Class III NRs preferentially bind as monomers to hexameric 5'-
AGGTCA-3' REs. However, stable monomeric binding requires
interaction between the CTE and a trinucleotide sequence ﬂanking
the hexameric RE (5'-trinucleotide). The CTE of, e.g., SF1 and the ERRs
harbors a ‘GRIP-box’, similar to ERα, which interacts with minor
groove DNA of the 5'-trinucleotide, thereby extending the protein–
DNA interaction surface beyond the core hexanucleotide RE [85].
Moreover, the sequence of this 5'-trinucleotide has also been shown
to be important in other aspects of class III NR function. For instance,
the consensus 5'-trinucleotide sequence of the ERRs is 5'-TNA-3', with
N being any nucleotide. However, the nature of the N nucleotide has
been shown to dictate whether ERRα binds REs preferentially as a
monomer (C/G at the N position) or as a homodimer (A/T at the N
position) [5]. Furthermore, it has been reported that ERRα only
recruits speciﬁc cofactors, such as PGC-1α, as a homodimer [4,5]. This
indicates that the sequence of the 5'-trinucleotide sequence may
directly dictate themode of binding and functional outcome of at least
a subset of class III NRs. In contrast to ERRα, both ERRβ and SF1 bind
REs almost exclusively as monomers. Following RE binding the CTE of
ERRβ and SF1 has been shown to loop back on itself and interact with
a speciﬁc surface of the core DBD, which has been suggested to ‘lock’
the conformation of the DNA bound receptor thereby contributing to
stable monomeric DNA binding [38,85].
While direct NR-DNA interactions, with either minor or major
groove DNA, are important determinants of selective RE binding for all
three classes of NRs, it is becoming clear that local structural features
of the DNA helix are also important in this regard (Fig. 3). Recent
reports suggest that such local structural features of REs and
surrounding DNA sequences may constitute an additional level of
DNA binding speciﬁcity by NRs and other TFs, by forming local
DNA structures that selectively favors binding by speciﬁc NRs or NR
subfamilies. In other words, RE sequences not expected to form direct
interactions with NRs may still be important for selective NR binding
and function. For instance, a recent genome-wide investigation of
ERα binding to REs revealed that the sequence of the 3 nucleotide
spacer is relatively conserved, and that the spacer sequence
modulates both the DNA binding and transactivation potential of
ERα [137], albeit no direct interaction of ERα with the ERE spacer
sequences has been reported. Similarly, the conformation and
ﬂexibility conferred by the spacer sequence has for other DNA
binding TFs been shown to be highly important for productive high
afﬁnity binding [143].
3. The hinge region and NR speciﬁcity
The hinge region was until recently thought to serve primarily as
a ﬂexible linker that allowed the DBD and LBD to adopt differentorientations relative to each other to facilitate RE binding and NR
dimerization under different conditions. However, numerous studies
have now shown that the hinge of many NRs contributes markedly to
receptor function through various molecular mechanisms. Because
the hinge region is poorly conserved between NRs (even among
subtypes of the same NR), the hinge very likely contributes to cell
type, NR subtype- and gene-speciﬁc functions of at least a subset of
NRs.
The hinge region of many NRs including PPARs [104], AR [64] and
GR [58] has been shown to provide interaction surfaces for cofactors,
which modulate the transactivation potential of these NRs. Further-
more, multiple PTM sites implicated in several aspects of NR function,
including modulation of cofactor recruitment and RE afﬁnity, have
been identiﬁed in the hinge region of many NRs. A recent study
established that SUMOylation of a speciﬁc lysine in the PPARα hinge
modulates transcriptional activation in a gene-dependent manner
[115]. It was furthermore shown that this differential effect on target
gene transcription is due at least in part to increased recruitment of
the corepressor NCoR in response to SUMOylation. Thus, this study
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whereas others are not.
4. The ligand binding domain (LBD)
Following the discovery of the RXRα LBD crystal structure [13], the
LBD structure of most NRs has been solved, all sharing a very similar
overall architecture. The LBD consists of 11–13 α-helices, and 2–4 β-
sheets that adopt the highly conserved tertiary structure of the NR
LBD. With almost no variation between different NRs, the LBD folds
into a globular domain often described as a ‘3-layer antiparallel α-
helical sandwich’. Activation of NRs by agonist binding involves
repositioning of the extreme C-terminal H12 (also referred to as the
AF2 helix) of the LBD relative to the rest of the LBD, thereby switching
the NR from an ‘off’ to an ‘on’ state [14,122,152] by forming a charge-
clamped hydrophobic cavity that speciﬁcally accommodates a general
structural motif present in most coactivators (Fig. 4). This motif has
the consensus sequence LXXLL (L, leucine; X, any residue) [26,52],
which adopts a two-turnα-helix that binds a cavity formed by speciﬁc
LBD helices including H3 and the AF2 helix. In response to antagonist
binding (or absence of agonist for some NRs) the AF2 helix is
repositioned to form an extended binding surface that is selectively
recognized by a structural motif, LXXXIXXX(L/I), referred to as a
corepressor nuclear receptor box (CoRNR box) present in common
corepressors [61]. The binding surfaces of CoRNR boxes and
coactivator LXXLL motifs partially overlap, indicating that coactivator
and corepressor binding are mutually exclusive. Moreover, the
binding surface of CoRNR boxes extends into regions that are usually
occupied by the AF2 helix in the active conformation, which supports
that corepressor binding (through CoRNR boxes) cannot occur when
the LBD is in its active state (Fig. 4) [111,113,129]. In addition, two
recent reports revealed that RARs and Rev-Erbs can also form an
antiparallel β-sheet with corepressors through a speciﬁc corepressor
interaction motif in H11 [79,113]. Agonist binding to RARs induces a
β-strand to α-helix transition of H11 that provokes corepressor
release and facilitates coactivator binding [79]. Besides serving as a
prime docking site for cofactors, the LBD is involved in other
mechanisms of NR function. The major NR-NR dimerization surface,Fig. 4. The AF2-helix is repositioned in response to the nature of the ligand bound.
(A) In the presence of antagonist, the position of the AF2-helix allows binding of
corepressors through extended CoRNR-box sequences. (B) Binding of agonist switches
the AF2-helix into a position that favors binding of coactivators. Moreover, in this
position the AF2-helix occupies part of the extended CoRNR-box binding surface and
thereby disfavors binding of corepressors. [PDB ID; (A) 1kkq, (B) 1k7l].which for all NRs that function as dimers is imperative to receptor
function, resides in the LBD.Moreover, ligand binding has been shown
to promote NTD-LBD interactions (e.g., as described for ERα and AR),
DNA binding, and NTD folding, for some NRs. In the context of gene-
speciﬁc transcriptional activation, it has been shown that different
types of agonists lead to activation of distinct sets of target genesmost
likely through differential cofactor recruitment e.g., as shown for ERβ
[107]. However, whether the LBD directly contributes to gene-speciﬁc
transcriptional activation through mechanisms independent of the
nature of the ligand bound remains to be shown.
5. The NTD confers gene-speciﬁc transactivation through
receptor-speciﬁc protein interactions
The NTD harbors the ligand-independent activation function 1
(AF1) [2,25,45,56,124] and is thought to be highly unfolded in
solution but to acquire higher order secondary structure as a result of
both inter- and intra-molecular interactions. In vitro studies indicate
that direct interactionwith speciﬁc protein partners induces folding of
the NTD of, e.g., AR, ERα and GR [75,76,156]. In general, induced
folding of the NTD correlates positively with activation potential of
the receptor. Interestingly, the NTD structure of several NRs has been
shown to be modulated by allosteric communication as a result of,
e.g., DNA binding, ligand binding or protein–protein interactions
conferred by other domains in the receptors. For instance, the PR DBD
and CTE serve as an interaction surface for speciﬁc cofactors, such as
Jun dimerization protein 2 (JDP2) [55], which has been shown to
promote induced folding of the NTD and stimulate activity of the AF1,
thus contributing to PR activity [154,155]. This has led to a model
where induced folding (i.e., a general disorder-to-order transition)
occurs as a result of interaction with other proteins or DNA (Fig. 5).
This model, referred to as the ‘induced ﬁt’ model, implies that the
unfolded NTD can adopt different conformations according to the
nature of the binding partner. Thus, the observation that the
transactivation proﬁle of a given NR may differ signiﬁcantly depend-
ing on the cellular context may at least in part be explained by
differential expression of interaction partners able to modify the
structure – and thus the transactivation potential – conferred by the
NTD.
The NTD almost completely lacks conservation, even within
subfamilies of NRs, such as PPARs (PPARα, PPARβ, PPARγ), ERs
(ERα and ERβ) or ERRs (ERRα, ERRβ and ERRγ), which suggests that
the functional roles of the NTD may be highly receptor-speciﬁc. For
instance, the ERα NTD has been shown to confer strong ligand-
independent transactivation potential in, e.g., reporter assays,
whereas the ERβ NTD under the same conditions does not [27].
Moreover, it has been shown that the ERα NTD is able to engage in
interdomain interactions with its own LBD (NTD-LBD interaction, N/C
interaction), whereas no such NTD-LBD interaction has been
demonstrated for ERβ yet. This type of interdomain communication
involving the NTDmodulates the transactivation potential of, e.g., ERα
by promoting recruitment of speciﬁc coactivators such as SRC-1 [96].
Similar functional N/C interactions have been described for AR [9,78],
and PR [30]. Studies using NR NTD chimeras and deletion mutants, in
which the NTD is either deleted or swapped between NRs demon-
strate that the NTD – at least for a subset of NRs – contributes to gene-
speciﬁc activation of target genes. For instance, swapping the NTD
between PPARα and PPARγ revealed that the NTD can act both as an
activator or repressor of transactivation in a gene-speciﬁc manner
[15,62]. Similarly, the use of AR/GR chimeras revealed that the AR NTD
is the sole determinant of AR-speciﬁc activation via an intragenic RE in
the AR gene known to be speciﬁcally activated by AR but not GR [44].
This study illustrates that the NTD contributes signiﬁcantly to gene-
speciﬁc transactivation by AR. Using a similar strategy, chimeras in
which the NTD was swapped between ERα and ERβ revealed that the
NTD is an important determinant of ligand-speciﬁc transcriptional
Fig. 5. The non-conserved NTD is disordered in solution but acquires high order structure in response to different cellular effectors, including cofactor interactions, DNA binding,
ligand binding to the LBD, and post translational modiﬁcations (PTMs). The NTD is thought to adopt a multitude of conformations in response to different effector cues, which
ultimately translates into NR-speciﬁc NTD-dependent transactivation of target genes.
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ERβ-selective target gene TGFβ-inducible early gene-1 (TIEG1)
requires the ERβ NTD, as deletion of the ERβ NTD or swapping the
ERα NTD into ERβ abolished activation of TIEG1 expression [51]. In
this study, it was further shown that both ERα and ERβ are able to
bind intronic REs controlling TIEG1 expression, but recruitment of
speciﬁc coactivators (SRC-1 and SRC-2) to this region required the
presence of the ERβ NTD. Interestingly, the ERα NTD has in other
studies been shown to interact with both SRC-1 and SRC-2 in vitro
[96,157] and to potentiate SRC-1 recruitment to agonist-bound ERα in
vivo. This illustrates that the role of speciﬁc NR domains in gene-
speciﬁc transactivation and recruitment of cofactors is dependent on
the cellular context.
A role of the NTD in NR subtype- and gene-speciﬁc functions has
been shown for the PRs (PR-A and PR-B), which are identical except
that PR-B contains an additional 164 amino acids in the NTD compared
to PR-A. PR-B has a much stronger activation potential than PR-A in
reporter assays, and it has been shown that PR-A and PR-B regulate
distinct sets of target genes under identical conditions in vivo [123],
which is at least in part due to differential ability to recruit cofactors
[41]. In this context, it has been suggested that following DNA binding,
the unique NTD of PR-B promotes NTD-dependent stabilization of
receptor structure as a result of intramolecular interactions between
the PR-B NTD and both the DBD (when bound to DNA), and the LBD in
response to ligand binding [146], which facilitates recruitment and
assembly of transcriptionally competent complexes to PR target genes
(Fig. 5).
The structure and function of NR NTDs are also affected by PTMs,
which may also contribute to gene-speciﬁc transcriptional activation
(Fig. 5). Phosphorylation of the NTD of several NRs results in increased
higher order secondary structure (e.g., increased α-helical content at
the expense of disordered random coil), which positively correlates
with the ability of NRs to recruit speciﬁc cofactors in an NTD-dependent manner. This was recently demonstrated for GR [37] and
ERβ [148]. Moreover, phosphorylation of different sites in the GR NTD
was recently reported to differentially affect the ability of GR to bind
REs and activate transcription of GR target genes [11,21]. Whether
such phosphorylations directly inﬂuence the properties of the DBD, or
whether the effects on DNA binding is mediated via effects on
interacting cofactors remains to be established. However, it is likely
that phosphorylations of the NTD of other NRs similarly affect the
ability of the respective NRs to bind to speciﬁc REs and activate target
genes.
Phosphorylation of the NTD has also been shown to modulate
other aspects of NR function, albeit it remains unclear whether these
mechanisms contribute to gene-speciﬁc transactivation by NRs. For
instance, phosphorylation of a speciﬁc residue in the PPARγ NTD was
reported to reduce ligand-afﬁnity of its LBD [135], thereby reducing its
transactivation potential. Moreover, NRs are known to be modiﬁed by
many other types of PTMs, including acetylation, ubiquitylation,
methylation, and glycosylation but so far the role of these modiﬁca-
tions in gene-speciﬁc transactivation remains elusive.
Additionally, SUMOylation of the AR NTD has been shown to
correlate with reduced transactivation of target genes [114]. Inter-
estingly, SUMO-speciﬁc proteases (SENPs), promote activity of AR by
de-conjugation of SUMO in the AR NTD in an RE-dependent manner
[68]. SENPs only de-SUMOylate (and thus activate) AR bound to
composite REs, consisting of multiple (i.e., two or more) REs in close
proximity of each other, whereas the activity of AR bound to single-
copy REs is not potentiated by SENPs. The number and location of NR
REs found in regulatory modules controlling speciﬁc genes varies
considerably. In this context, the ability of SENPs to selectively
modulate the activity of AR, when bound to regulatory modules
containing multiple REs, strongly indicates that this represents
another mechanism contributing to gene-speciﬁc activation of target
genes by AR.
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NTD allows it to adopt a multitude of conformations, and to acquire
higher order structure by PTMs, interaction with cofactors, and/or
allosteric mechanisms (e.g., as a result of NTD PTMs or DNA or ligand
binding to the DBD or LBD, respectively). Therefore, the highly
receptor- and context-speciﬁc functions of the NTD indicate that this
non-conserved domain is an important determinant of subtype-, cell
type-, and gene-speciﬁc functions of many NRs.
6. Dynamic association between NRs and chromatin
Genome-wide studies of NR binding have revealed approximately
3,500-40,000 binding sites depending on the NR and the species
under investigation [18,99,103,128]. Furthermore, NRs typically bind
to composite elements separated by 1–5 nucleotides, which gives a
core RE of 13–17 bp. As the human genome consists of approximately
3 billion base pairs, this suggests that the REs for a given NR comprise
roughly 0.1‰ of the genome. The question is then, how do NRs locate
their cognate REs in this sea of DNA sequences?
Several studies have now demonstrated that the interactions
between TFs including NRs and the chromatin template in living cells
are highly dynamic [10,48]. Chromatin binding proteins such as TFs
rapidly traverse the nucleus by energy-independent passive diffusion,
where they transiently and non-speciﬁcally interact with the
chromatin template [48,100]. This allows TFs such as NRs to rapidly
scan the genome in three dimensions to locate their sparsely
distributed binding sites. When the receptor encounters a cognate
RE, it may form a productive interaction with the chromatin template,
which is typically accompanied by local remodeling of the chromatin
structure [54,65,158]. The formation of a productive binding event has
previously been assumed to stably tether the TF to the chromatin
template based on in vitro studies with naked DNA. Surprisingly
however, GR binding to the mouse mammary tumor virus (MMTV)
tandem array, containing 800 to 1200 GR binding sites, in living cells
was also demonstrated to be highly dynamic in nature (residence
time in the time scale of seconds) by ﬂuorescence recovery after
photobleaching (FRAP) analyses [93]. This highly dynamic association
with chromatin embedded target sites has subsequently been
demonstrated for several other TFs such as NF-κB [12], PR [121], ER
[136], AR [73], and CUP1 [71] as well as cofactors such as Brahma
(BRM) and Brahma related gene 1 (BRG1) [66]. Thus, despite a slight
increase in residence time upon formation of a productive binding
event [73,140], interactions between NRs and their target REs are
highly dynamic. Interestingly, rapid dissociation of NRs from
productive binding events in chromatin has been linked to ATP-
dependent chromatin remodeling activities [34,102,121], suggesting
that eviction of NRs from binding sites is an active process. This
mechanism of active release may allow NRs to rapidly respond to
changing levels in ligand and may thus be important for the
physiological function of NRs. The proteasome system has also been
shown to be important for the rapid exchange of GR at the MMTV
array, suggesting that proteasomal degradation of GR and/or GR-
associated factors is also coupled to the eviction of this receptor from
its target sites [140].
In addition to the rapid dynamics of NR associationwith chromatin
described above, binding of some NRs to their target sites has also
been shown to oscillate on a much larger time scale (in the order of
minutes and hours). These oscillatory interactions between NRs and
target REs were ﬁrst demonstrated for ER [134] and have subse-
quently been shown to be accompanied by cycles of coordinated
cofactor recruitment [97,134] as well as cycling of histone marks [97]
and DNA methylation [70,95]. This suggests that the outcome of
productive ER binding events (i.e., epigenetic marks and recruited
cofactors) may feedback on the binding of ER itself to create this
oscillatory pattern of binding. Cycling at target REs has since been
reported for TR [87] and AR [69] suggesting that this may be a generalmechanism of NR action at least for the endocrine receptors. The
physiological function of this cycling behavior is not fully understood,
but it may be important for eliciting the appropriate transcriptional
response to changing hormone levels at speciﬁc gene promoters.
NR cycling at target sites may also stem from oscillations in
hormone levels as has been described for GR. Glucocorticoids are
released from the adrenal gland in an ultradian fashion [83] and this
leads to oscillations in GR binding to target REs and GR target gene
transcription [141]. The net result is a markedly different transcrip-
tional response compared to constant levels of hormone [141],
indicating an important physiological function of this oscillation
pattern [29].
It is important to distinguish between the rapid exchange of NRs at
REs (time scale of seconds, determined by FRAP in living cells) and the
slower oscillations described above (time scale of minutes to hours,
determined by chromatin immunoprecipitation (ChIP)). The former
describes the residence time of NRs at target REs in a single cell and is
thus inﬂuenced by the local cellular milieu including cofactor
availability, chromatin structure etc. The latter describes the equilib-
rium of the association between the NR and the target RE averaged
over a cell population. This oscillation pattern is the result of a
complex interplay between hormone, cofactors, epigenetic marks,
and the receptor that is still poorly deﬁned.
7. DNA looping is a key aspect of NR transactivation
Hitherto the majority of the identiﬁed functional NR regulatory
elements map relatively close to and upstream from the transcrip-
tional start site (TSS). However, unbiased global analyses of NR
binding have shown that even though NR binding is enriched at gene
promoters relative to the rest of the genome, most NR binding sites
are found distant from the TSS in introns and intergenic regions
[17,81,103,139]. It remains an open question how many of the
thousands of binding sites represent direct binding of NRs to DNA.
Furthermore, it is unknown to what extent all these sites are involved
in transcriptional regulation.
The large distance between most NR binding sites and target gene
promoters necessitates studies on the three-dimensional structure of
the genome to understand the molecular mechanisms of NR function.
Recently, long-range looping between distant regulatory sites
occupied by sequence- speciﬁc TFs including NRs and gene promoters
has been demonstrated for selected gene loci using the chromosome
conformation capture (3C) technology [16,40,49,82,105] and for the
entire genome using chromatin interaction analysis by paired-end tag
sequencing (ChIA-PET) [36]. Ruan and coworkers identiﬁed multiple
intrachromosomal interactions between distant ERα binding sites and
proximal gene promoters, but very few interchromosomal interac-
tions [36]. The distal ERα binding sites involved in intrachromosomal
interactions are enriched in RNAPII binding and genes in the
proximity of these sites are signiﬁcantly more activated by estradiol
compared to genes in the proximity of non-interacting binding sites.
This suggests that these long-range chromatin interactions are
functionally important for ERα transactivation. These important
data indicate that DNA looping that brings distant enhancers and
proximal promoters together is an essential aspect of NR-induced
activation of target genes.
8. Crosstalk with other TFs
Genomics studies have demonstrated an extensive overlap between
the binding proﬁles of NRs and other TFs [17,81,89,103,142]. This
suggests that NR action can be ﬁne-tuned in a gene- and cell-speciﬁc
manner by modulating the expression and activity of cooperating TFs
(Fig. 3). The molecular mechanisms underlying this crosstalk can be






























































Fig. 6. Molecular mechanisms of crosstalk between NRs and other TFs. (A) Pioneering
factors remodel the chromatin template prior to NR binding. (B–D) NR and cooperating
TFs interact with different REs and cooperatively recruit coactivator complexes. (E) NRs
and cooperating TFs interact with the same or overlapping REs resulting in dynamic
exchange of transcriptional complexes. (F) Tethering of ligand-bound NR to
inﬂammatory TFs.
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Recently, chromosome-wide proﬁles of ER binding revealed the
enrichment of motifs for Forkhead TFs at ER binding sites [17]. ChIP
assays revealed that FoxA1 actually occupied a subset of ER binding
sites prior to stimulation with the ER agonist estradiol. Furthermore,
these sites mapped to open chromatin regions and depletion of FoxA1
abolished estradiol-induced ER binding and target gene activation
[17,31,89]. FoxA1 has also recently been shown to facilitate GR
binding to the MMTV array through opening of the chromatin
structure [8]. Together with the observation that FoxA1 can bind to
histones and open compacted nucleosome arrays in vitro [23], this led
to the concept that FoxA1 acts as a pioneering factor for NRs such as
ER and GR by locating target sites in closed chromatin and remodeling
the chromatin template, thereby assisting NR binding to target REs
upon agonist stimulation (Fig. 6A). Pioneering factors such as FoxA1
thereby deﬁne the subset of potential REs that have an open
chromatin structure and are prone to NR binding, which at least
partly explains the discrepancy between the high number of potential
REs in the genome and the relatively low number of experimentally
identiﬁed binding sites [17]. Thus, pioneering factors assist in deﬁning
cell-speciﬁc binding proﬁles for NRs by modulating the chromatin
landscape of the cell, thereby leading to a cell-speciﬁc response to NR
activation [31,89].
Crosstalk between NRs and other TFs may also arise from adjacent
binding to their respective REs as has beenproposed as amechanismof
direct crosstalk between several NRs and cooperating TFs on
chromatin, including PPARγ-CCAAT/enhancer binding protein α (C/
EBPα), GR-C/EBPβ, and ER-RARα [53,81,103,127,142,153] (Fig. 6B).
Alternatively, cooperative interactions may potentially also occur
between NRs and TFs bound at distant sites through long-range
chromosomal loops (Fig. 6C, D) as described above for enhancer–
promoter interactions. Regardless of the relative genomic locations of
the direct TF-DNA contacts, juxtaposition of two ormore TFs at a given
site may facilitate transcription by creating a cofactor interaction
surface that results in a more efﬁcient recruitment of coactivators
(Fig. 6B–D). Alternatively, different TFs may contact and recruit
distinct coactivator complexes [43,88] that work together to induce
transcriptional activation. Instead of recruiting a common cofactor
complex through simultaneous binding to different REs (Fig. 6B–D),
cooperating TFs may also alternate in binding to the same or
overlapping REs (Fig. 6E). The short residence time of TFs on individual
REs limits competition for the common site and allows dynamic
exchange of transcriptional complexes. Efﬁcient binding of cooperat-
ing TFs to shared sites has in many cases been shown to be dependent
on the presence of both TFs [22,53,127,142], suggesting that efﬁcient
recruitment of cofactor complexes by cooperating factors stabilizes TF
binding. Alternatively, direct interactions between TFsmay stabilize TF
binding to DNA as has been reported for c-Myc and C/EBPβ [145].
Taken together, these ﬁndings suggest that the expression and activity
of cooperating TFs regulate NR function in a gene- and cell-speciﬁc
manner by directly targeting shared regulatory sites in the genome.
In addition to activating target gene transcription from their
cognate REs, several NRs have been known for a long time to
speciﬁcally repress inﬂammatory signaling through tethering to
inﬂammatory TFs (e.g., Nuclear Factor-κB (NF-κB) and Activator
Protein-1 (AP-1)) and recruitment of corepressors (Fig. 6F). Upon
glucocorticoid binding, monomeric GR associates with AP-1 and
inhibits transactivation of AP-1 target genes by stabilizing formation
of a corepressor complex at target regulatory elements [67,120,159]. A
similar mechanism has been described for repression of NF-κB
signaling by agonist-bound PPARγ [108]. Interestingly, upon binding
of agonist, the PPARγ LBD is SUMOylated, and this is required for
transrepression, but not transactivation, by this receptor [63,108].
Thus, this SUMOylation has been suggested to constitute a molecular
switch between transactivation and transrepression by PPARγ [108].
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interplay between NRs and other TFs on the chromatin template
described above allows for gene-speciﬁc regulation of NR-mediated
transcription by other TFs. As more and more studies describing NR
crosstalk with other TFs on a genome-wide level emerge, it is
becoming increasingly clear that this is likely to represent an
important general mechanism through which other signaling path-
ways can speciﬁcally ﬁne-tune NR signaling in a gene-speciﬁc
manner. Interestingly, clusters of up to ﬁve different TFs that co-
occupy speciﬁc regulatory elements in the genome have been
identiﬁed in embryonic stem cells, suggesting a convergence of
multiple signaling pathways at speciﬁc genomic loci in these cells
[22]. This indicates that entire networks of TFs can actually directly
cooperate at speciﬁc genomic loci to ﬁne-tune transcription of target
genes. Furthermore, Glass and coworkers have recently demonstrated
that cooperation between hematopoetic TF PU.1 and lineage-speciﬁc
TFs in macrophages and B-cells results in cell-speciﬁc binding proﬁles
of PU.1. Similarly, Lazar and colleagues have recently shown that PU.1
may assist in deﬁning the macrophage-speciﬁc PPARγ binding proﬁle,
which is distinct from that in adipocytes [80]. This emphasizes the
importance of direct crosstalk between TFs on chromatin for
speciﬁcally regulating TF activity in a gene- and cell type-speciﬁc
manner. Future studies should aim at extending ﬁndings of NR
crosstalk with other TFs by identifying TF networks containing NRs
that target speciﬁc sites in the genome. Furthermore, delineating the
molecular mechanisms underlying crosstalk within these networks
represents an important challenge as this may reveal a novel avenue
for speciﬁc targeting of NR signaling by clinical compounds to treat
NR-linked diseases such as metabolic diseases and cancer.
Concluding remarks
Gene-speciﬁc transactivation by NRs is governed by multiple
layers of receptor-speciﬁc interactions. First, the non-conserved CTE
of the DBD interacts speciﬁcally with the DNA sequences surrounding
the core RE and thereby directly affects DNA binding for a subset of
NRs. Second, the highly unstructured and non-conserved NTD has
been shown to affect NR function in a gene-speciﬁc manner mainly
through cofactor interactions. Finally, recent genome-wide binding
proﬁles have revealed an extensive crosstalk between NRs and other
sequence-speciﬁc TFs on the chromatin template, which is likely to
represent an importantmechanism throughwhich NR function can be
modulated by other transcriptional pathways in a gene-speciﬁc
manner. The extent and mechanism of this crosstalk is only starting
to emerge; however, it is likely to involve direct protein–protein
interactions between TF complexes binding to adjacent as well as
distal sequences. In addition, TFs may work together by binding
sequentially to overlapping sites. A better understanding of this
crosstalk is likely to reveal novel potential therapeutic targets for the
treatment of diseases linked to NR malfunction.
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